Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by EDMUND KWOK-MING LI
Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients With Psoriatic Arthritis Receiving Tumor Necrosis Factor- Blockers
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Related publications
Weight Loss and Achievement of Minimal Disease Activity in Patients With Psoriatic Arthritis Starting Treatment With Tumour Necrosis Factor Α Blockers
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Erratum To: Anti-Tumor Necrosis Factor-Α Therapy and Changes of Flow-Mediated Vasodilatation in Psoriatic and Rheumatoid Arthritis Patients
Internal and Emergency Medicine
Internal Medicine
Emergency Medicine
Cost of Tumor Necrosis Factor Blockers Per Patient With Rheumatoid Arthritis in a Multistate Medicaid Population
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Effectiveness and Safety of Adalimumab in Patients With Ankylosing Spondylitis or Psoriatic Arthritis and History of Anti-Tumor Necrosis Factor Therapy
Arthritis Research and Therapy
Rheumatology
Allergy
Immunology
PMS5 Data Visualization of Treatment Patterns of Medicare Psoriatic Arthritis Patients Who Initiate Tumor Necrosis Factor Therapy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Tumor Necrosis Factor Α Antagonists in the Treatment of the Patients With Rheumatoid Arthritis
Reumatologia
Rheumatology
Allergy
Immunology
Maintenance of Cytomegalovirus-Specific CD4pos T-Cell Response in Rheumatoid Arthritis Patients Receiving Anti-Tumor Necrosis Factor Treatments
Arthritis Research and Therapy
Rheumatology
Allergy
Immunology
Effect of the Biological Drug Etanercept on Tumor Necrosis Factor-Α Levels in Psoriatic Patients
Iraqi Journal of Science
Genetics
Molecular Biology
Geology
Biochemistry
Computer Science
Biotechnology
Chemistry
Predictors of Treatment Initiation With Tumor Necrosis Factor-Α Inhibitors in Patients With Rheumatoid Arthritis
Journal of Managed Care Pharmacy
